← Analyst Upside
AU · rank #5 · 2026-07-27
ABVX
PARIS · EUR · $11.21B (USD)
SignalStrong Buy7.8strength 7.8 / 10
verdict · PROCEED
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 2.204 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.47 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 1 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $138.56 | +22.8% |
| Momentum acceleration 3-month minus 12-month momentum. | -6.42% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.29 |
| Gross margin TTM | +100.0% |
| 52w high | $139.00 |
| Market cap (USD) | $11.21B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Abivax SA is a clinical-stage biopharmaceutical company focused on developing its lead once-daily oral miR-124 enhancer, obefazimod, for chronic inflammatory diseases.
Rationale
Positive Phase 3 ABTECT maintenance trial results and the planned Q4 2026 FDA NDA submission directly support the 100% analyst revision agreement and the 22.8% price upside.
Material risks
- 1Regulatory or clinical failure of obefazimod, the company's sole late-stage candidate, which has no current market approvals or commercial revenues.
- 2Commercial launch execution risks and intense competition in the ulcerative colitis market without any long-term contracted backlog or sole-supplier protections.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.
OpenAI
Proceed
Claude
Caution
Gemini
Proceed